Combined modality therapy for limited-disease Small Cell Lung Cancer

Current Treatment Options in Oncology

Volumn 6, Issue 1, 2005, Pages 69-74

  Raez, Luis ^b   Samuels, Michael ^b   Lilenbaum, Rogerio ^a  

^a Mount Sinai Comprehensive Cancer Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TANOMASTAT; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG INTERACTION; DRUG MEGADOSE; DRUG POTENTIATION; ESOPHAGITIS; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; LUNG NODULE; LUNG SMALL CELL CANCER; LUNG SURGERY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; SMOKING; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY;

EID: 13544276539     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0014-1     Document Type: Review

References (22)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Page NC, Read WL, Tierney RM, et al.: The epidemiology of small cell lung carcinoma [abstract 1216]. Proc Am Soc Clin Oncol 2002, 21:305a.
3. Quero Blanco C, Lopez-Picazo JM, Boan J, et al.: Initial staging of small cell lung cancer patients with 18F FDG-PET and conventional imaging techniques [abstract 2618]. Proc Am Soc Clin Oncol 2003, 22:651.
4. Chute JP, Chen T, Feigal E, et al.: Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999, 17: 794-1801.
5. Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 1999, 340:265-271.
6. Kosmidis P, Samantas E, Fountzilas G, et al.: Cisplatin/etoposide versus carboplatin/etoposide and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 1994, 21(Suppl 6):23-30.
7. Glisson B, Scott C, Komaki R, et al.: Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small cell lung carcinoma: Results of Radiation Therapy Oncology Group trial 93-12. J Clin Oncol 2000, 18:2990-2995.
8. Ettinger DS, Seiferheld WF, Abrams RA, et al.: Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients with limited disease (LD) small cell lung cancer (SCLC): preliminary results of RTOG 95-09 [abstract]. Proc Am Soc Clin Oncol 2000, 19:490a.
9. Niell HB, Herndon JE, Miller AA: Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer [abstract 2662]. Proc Am Soc Clin Oncol 2002, 21: 93a.
10. Schiller JH, Adak S, Cella D, et al.: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19: 114-2122.
11. Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002, 346:85-91.
12. Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992, 327:1618-1624.
13. Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993, 11: 36-344.
14. Choi NC, Herndon J, Rosenman J, et al.: Long-term survival data from CALGB 8837: radiation dose escalation and concurrent chemotherapy in limited-stage small cell lung cancer. Possible radiation dose-survival relationship [abstract 1190]. Proc Am Soc Clin Oncol 2002, 21:298a.
15. Auperin A, Arriagada R, Pignon JP, et al.: Prophylactic crania irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999, 341:476-484.
16. Vines EF, Le Pechoux C, Arriagada R: Prophylactic cranial irradiation in small cell lung cancer. Semin Oncol 2003, 30: 8-46.
17. Shepherd FA: Surgical management of small cell lung cancer. In Lung Cancer: Principles and Practice. Edited by Pass HI, et al.: Baltimore: Lippincott Williams & Wilkins; 2000:967-980. (Au: could you add 2 more names after Pass HI)
18. Lad T, Piantadosi S, Thomas P, et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106(Suppl ):320-323.
19. Shepherd F, Giaccone G, Debruyne C, et al.: Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer following response to first-line chemotherapy: An NCIC and EORTC study [abstract]. Pro Am Soc Clin Oncol 2001, 20:1.
20. Johnson BE, Fisher B, Fisher T, et al.: Phase II study of STI571 (Gleevec) for patients with small cell lung cancer [abstract 1171]. Proc Am Soc Clin Oncol 2002, 21:293a.
21. Grant SC, Kris MG, Houghton AN, et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999, 5:1319-1323.
22. Giaccone G, Debruyne C, Felip E, et al.: Phase III study of BEC/BCG vaccination in limited disease small cell lung cancer patients following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study) [abstract 7020]. Proc Am Soc Clin Oncol 2004, 18.